Peptic ulcer disease (PUD) remains a prevalent gastrointestinal disorder with significant morbidity and mortality rates. The management of PUD has evolved significantly over the past few decades due to advancements in diagnostic tools, pharmacological treatments, and an improved understanding of the disease's pathophysiology.
Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary etiological factors for PUD. The disruption of the mucosal barrier, leading to gastric acid damage, is a common pathway in ulcer development. Understanding this pathophysiology has been pivotal in designing effective treatment strategies.
Endoscopy remains the gold standard for diagnosing PUD, providing direct visualization and biopsy opportunities. However, non-invasive tests for H. pylori, such as urea breath tests and stool antigen tests, have improved diagnostic accuracy and patient comfort.
Proton pump inhibitors (PPIs) and H. pylori eradication therapy form the cornerstone of PUD management. PPIs suppress gastric acid secretion, promoting ulcer healing, while H. pylori eradication prevents ulcer recurrence. Recent studies highlight the potential of potassium-competitive acid blockers as a promising alternative to PPIs.
For NSAID-induced ulcers, discontinuing NSAIDs is ideal. However, if this is not feasible, co-prescription of PPIs or the use of selective cyclooxygenase-2 inhibitors can mitigate gastrointestinal risks.
While the need for surgical intervention has decreased due to effective medical therapy, it remains crucial for managing complications such as bleeding, perforation, or gastric outlet obstruction.
The management of PUD has come a long way, with advancements in understanding its pathophysiology, diagnostic methods, and treatment options. Continual research and innovation are imperative to further enhance patient outcomes and reduce disease burden.
1.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
2.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Radiation therapy can promote amphiregulin, which increases growth of metastases
5.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
1.
Learning from Uncommon Inherited Bleeding Disorder Presentations
2.
Essential Strategies in Hematology for Healthcare Excellence
3.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
4.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
5.
Lymphomatoid Papulosis: What You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation